CoChat

A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome

Open access
Gross, Oliver, Tönshoff, Burkhard, Weber, Lutz T., Pape, Lars, Latta, Kay, Fehrenbach, Henry, Lange-Sperandio, Baerbel, Zappel, Hildegard, Hoyer, Peter, Staude, Hagen, König, Sabine, John, Ulrike, Gellermann, Jutta, Hoppe, Bernd, Galiano, Matthias, Hoecker, Britta, Ehren, Rasmus, Lerch, Christian, Kashtan, Clifford E., Harden, Markus, Boeckhaus, Jan, Friede, Tim, Koziolek, Michael, Bramlage, Carsten Paul, Weber, Frauke, Albrecht-Nock, Tanja, Sonntag, Joseph, Frese, Jenny, Kettwig, Matthias, Hilgers, Reinhard, Hansen, Matthias, Wedekin, Mirja, Meyer, Nicole, Klaiber, Susanne, Gessner, Michaela, Liebau, Max, Vogt-Weigeldt, Anne-Kristin, Jungraithmayr, Therese, Ponsel, Sabine, Jacoby, Ulrike, Konrad, Martin, Kranz, Brigitta, Koenig, Jens, Loechtermann, Lisa, Pohl, Michael, Husain, Ralf, Mueller, Katrin, Thumfart, Julia, Schalk, Gesa, Feldkoetter, Markus, Schmidt, Sabine, Sauerstein, Katja, Muschiol, Evelin, Billing, Heiko, Wilkening, Frauke · 2020 · Kidney International
Cited by 160

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Children with Alport syndrome develop renal failure early in life. Since the safety and efficacy of preemptive nephroprotective therapy are uncertain we conducted a randomized, placebo-controlled, double-blind trial in 14 German sites of pediatric patients with ramipril for three to six years plus six months follow-up to determine these parameters. Pretreated children and those whose parents refused randomization became an open-arm control, which were compared to prospective real-world data from untreated children. The co-primary endpoints were safety (adverse drug reactions) and efficacy (time to progression). Out of 66 oligosymptomatic children, 22 were randomized and 44 joined the open-arm comparison. Ramipril therapy showed no safety issues (total of 216.4 patient-years on ramipril; adverse event rate-ratio 1.00; 95% confidence interval 0.66-1.53). Although not significant, our results cautiously showed that ramipril therapy was effective: in the randomized arm, Ramipril decreased the risk of disease progression by almost half (hazard ratio 0.51 (0.12-2.20)), diminished the slope of albuminuria progression and the decline in glomerular filtration. In adjusted analysis, indications of efficacy were supported by prospective data from participants treated open label compared with untreated children, in whom ramipril again seemed to reduce progression by almost half (0.53 (0.22-1.29)). Incorporating these results into the randomized data by Bayesian evidence synthesis resulted in a more precise estimate of the hazard-ratio of 0.52 (0.19-1.39). Thus, our study shows the safety of early initiation of therapy and supports the hope to slow renal failure by many years, emphasizing the value of preemptive therapy. Hence, screening programs for glomerular hematuria in children and young adults could benefit from inclusion of genetic testing for Alport-related gene-variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.kint.2019.12.015

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Gross, O., Tönshoff, B., Weber, L. T., Pape, L., Latta, K., Fehrenbach, H., Lange-Sperandio, B., Zappel, H., Hoyer, P., Staude, H., König, S., John, U., Gellermann, J., Hoppe, B., Galiano, M., Hoecker, B., Ehren, R., Lerch, C., Kashtan, C. E., Harden, M., Boeckhaus, J., Friede, T., Koziolek, M., Bramlage, C. P., Weber, F., Albrecht-Nock, T., Sonntag, J., Frese, J., Kettwig, M., Hilgers, R., Hansen, M., Wedekin, M., Meyer, N., Klaiber, S., Gessner, M., Liebau, M., Vogt-Weigeldt, A.-K., Jungraithmayr, T., Ponsel, S., Jacoby, U., Konrad, M., Kranz, B., Koenig, J., Loechtermann, L., Pohl, M., Husain, R., Mueller, K., Thumfart, J., Schalk, G., Feldkoetter, M., Schmidt, S., Sauerstein, K., Muschiol, E., Billing, H., & Wilkening, F.
Venue
Kidney International
Publisher
Elsevier BV
Published
2020-06
Volume
97
Issue
6
Pages
1275-1286
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2999032424
Cited by
160
References
3
FWCI
13.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.